

# Nivolumab and Ipilimumab Approved as Immunotherapy Treatments in the USA

Posted On: 03/10/2020

Author: Philip Turton

On 2 October 2020, the American Food & Drug Administration approved a combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co) and ipilimumab (YERVOY, Bristol-Myers Squibb Co) as a first-line treatment for adults with unresectable mesothelioma. Randomised open-label trials suggest an improvement in overall survival in the order of approximately 25% when compared with chemotherapy.

The full announcement is available [here](#).

As yet, the treatment is not approved for use in the UK.

Downloaded From:

<https://ropewalk.co.uk/blog/nivolumab-and-ipilimumab-approved-as-immunotherapy-treatments-in-the-usa/>